



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 15th April 2019

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the 11th February 2019 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

Nil

Ex-panel

• **Sodium Valpoate 250mg and 500mg Granules (Chronosphere®)**

Request for addition of the remaining strengths of Sodium Valproate granules (Chronospheres®) to the formulary for children with swallowing difficulties who require larger doses.

Strengths already included on the formulary: 50mg and 100mg

More cost effective to have the higher strength granules on the formulary: The 250mg and 500mg granules are the same price as a box of 100mg granules - £30 for a pack of 30 sachets so more cost effective than using 5 x 100mg sachets.

Outcome: Approved for addition to the formulary

• **Insulin Insulatard Innolet Pen**

Request for the Insulin Insulatard Innolet pen to be added to the formulary.

Insulin Insulatard vials and cartridges are already included on the formulary.

The Innolet pen is the only disposable pen device available. It is a good option for patients who have reduced manual dexterity or impaired vision as the dial is much larger than on Flexpens/Kwikpens.

Outcome: Approved for addition to the formulary

Removals

Nil

NICE Approved drug applications

Nil

Pharmacoeconomic Board requests

IVIG for Autoimmune (Limbic) Encephalitis

Approved by the Pharmacoeconomic Board on 12/03/19

Outcome: Noted

Rituximab for Autoimmune (Limbic) Encephalitis

Approved by the Pharmacoeconomic Board on 03/04/19

Outcome: Noted



4.2 Trust Medicines Policy

- **TMP: Section 20 - Unlicensed use of a licensed medicine**

General update to ensure clarity around requirements for unlicensed medicines and unlicensed use of a licensed medicine.

Decision: Approved

- **Policy for the administration of vaccines within the HIV/GUM Directorate by Healthcare Assistants, Assistant Practitioners and Healthcare Advisors**

Extended to Health Advisors operating under this policy.

Decision: Approved

- **TMP: Section 37 - TMP: Section 34 - Supply and administration of medicines by Non-registered Healthcare Practitioners**

Updated to include extension to Health Advisors working under:

- Administration of vaccines within HIV/GUM Directorate by Health Care Assistants, Assistant Practitioners and Health Advisors.

Decision: Approved

- **Proposed changes to the Trust Medicines Policy in light of the introduction of the role of the Nursing Associate**

Proposed changes to Trust Medicines Policy in light of introduction of Nursing Associate role

Decision: Approved

- **TMP: Section 8 - Administration of medicines**

Updated in light of introduction of Nursing Associate role

Decision: Approved

- **TMP: Section 6 - Controlled Drugs**

Updated in light of introduction of Nursing Associate role

Decision: Approved

- **TMP: Section 17 - Injectable Medicines Policy**

Updated in light of introduction of Nursing Associate role

Decision: Approved

- **Changes to Trust Adult IV Administration Policy**

Updated to include:

Clarification in the Definition Section relating to flushing IV lines.

New Monographs:

- Artesunate IV - Not listed before in the IV Policy
- Posaconazole IV - Newly approved for addition to the formulary in February 2019

Updates:

- Vitamin K - Reference updated to signpost the reader accordingly to various vitamin monographs.

Decision: Approved

4.3 Medicines Optimisation

Nil

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

**TA565 - Benralizumab for treating severe eosinophilic asthma
Formulary status / Action**



Nil action - Not applicable - CWFT not a specialist respiratory centre

TA566 - Cochlear implants for children and adults with severe to profound deafness

Formulary status / Action

Nil action for Trust Formulary as this a medical device. Will be escalated to Clinical Governance to follow up with relevant consultant.

TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

Formulary status / Action

Nil action - Not applicable - Condition not treated at CWFT

TA568 - Abatacept for treating psoriatic arthritis after DMARDs

Formulary status / Action

Nil - Terminated appraisal

TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Formulary status / Action

Currently included on the formulary.

Numbers likely to treat at CWH site: N/A

Numbers likely to treat at WMUH site: 5-6 patients per year.

TA570 - Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (Terminated appraisal)

Formulary status / Action

Nil - Terminated appraisal

TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Formulary status / Action

Add to the formulary following receipt of a signed application form from the Oncology Team at CWH site

a) NICE Highly Specialised Technologies published since last meeting

0 Highly Specialised Technologies published

4.5 IVIG requests

- **IVIG issues for February 2019 - CW site**

There were 6 IVIG issues in March 2019, with 3 new requests

Decision: Approved

- **IVIG issues for February 2019 - WMUH site**

There were 16 IVIG issues in February 2019, with 6 new requests

Decision: Approved

- **IVIG issues for March 2019 - WMUH site**

There were 19 IVIG issues in March 2019, with 3 new requests

Decision: Approved

4.6 Items for noting

- **CCP Monthly Report - March 2019**

Clinical Commissioning Pharmacy Report for March 2019

Decision: Noted



- **MHRA Drug Safety Update - March 2019**

MHRA update for March 2019

Decision: Noted

4.7 Meeting minutes for noting

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - February 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - February 2019

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - March 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - March 2019

Decision: Noted

- **Chemotherapy Service Group - February 2019**

Minutes from Chemotherapy Service Group - February 2019

Decision: Noted

4.8 Additional papers to go to Trust Patient Safety Group

Nil

5. Any other business

Nil

6. Date of next meeting

Date: Monday 13th May 2019

Time: 8am-9am

Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)

Closing date: 26th April 2019